US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kyverna Therapeutics

3.47

+0.400013.03%

Post-market: 3.540.0700+2.02%19:17 EDT

Volume:852.40K

Turnover:2.87M

Market Cap:149.97M

PE:-1.03

High:3.61

Open:3.15

Low:3.10

Close:3.07

Loading ...

Overview Company News Filings

Kyverna Therapeutics Inc. Conducted Annual Stockholders Meeting

Kyverna Therapeutics Inc. CEO to Present at Jefferies Global Healthcare Conference

Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases

Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright

MT Newswires Live

Kyverna Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Kyverna Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS

Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Kyverna Therapeutics, Inc. (KYTX) Receives a Hold from H.C. Wainwright

Kyverna Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Q1 EPS $(1.03) Misses $(0.99) Estimate

Kyverna Therapeutics Reports Q1 2025 Net Loss of $44.6M, EPS of $1.03 Amid Increased R&D and G&A Expenses

Kyverna Therapeutics Inc: on Track for Topline Data in 1H 2026

THOMSON REUTERS

Kyverna Therapeutics Inc - Anticipates Bla Filing for Kyv-101 in 1H 2026

THOMSON REUTERS

Kyverna Therapeutics Inc - Reports Cash Runway Into 2027

THOMSON REUTERS

Kyverna Therapeutics Inc expected to post a loss of $1.11 a share - Earnings Preview

BRIEF-Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To Time - SEC Filing

Kyverna Therapeutics Files for Offering of up to $50 Mln Common Stock From Time to Time - SEC Filing

THOMSON REUTERS

Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.

Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KYTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":3.47,"timestamp":1750968000000,"preClose":3.07,"halted":0,"volume":852401,"hourTrading":{"tag":"盘后","latestPrice":3.54,"preClose":3.47,"latestTime":"19:17 EDT","volume":2221,"amount":7775.8702512,"timestamp":1750979855622},"delay":0,"floatShares":22191720,"shares":43218873,"eps":-3.366184,"marketStatus":"Post-Mkt","change":0.4,"latestTime":"06-26 19:31:27 EDT","open":3.15,"high":3.605,"low":3.1,"amount":2870459.8560594,"amplitude":0.164495,"askPrice":3.58,"askSize":100,"bidPrice":3.42,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-3.366184,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750982400000},"marketStatusCode":4,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":3.07,"postHourTrading":{"tag":"盘后","latestPrice":3.54,"preClose":3.47,"latestTime":"19:17 EDT","volume":2221,"amount":7775.8702512,"timestamp":1750979855622},"volumeRatio":2.210566,"impliedVol":1.5676,"impliedVolPercentile":0.944},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":22191720,"roa":"-31.08%","roe":"-49.72%","lyrEps":-3.325379,"volumeRatio":2.210566,"shares":43218873,"dividePrice":0,"high":3.605,"amplitude":0.164495,"preClose":3.07,"low":3.1,"week52Low":1.78,"pbRate":"0.67","psRate":"531.81","week52High":11.4,"institutionHeld":0,"latestPrice":3.47,"committee":0.960784,"eps":-3.366184,"divideRate":0,"volume":852401,"delay":0,"ttmEps":-3.366184,"open":3.15,"prevYearClose":3.74,"prevWeekClose":3.07,"prevMonthClose":2.55,"prevQuarterClose":1.93,"fiveDayClose":2.91,"twentyDayClose":2.55,"sixtyDayClose":1.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540704647","title":"Kyverna Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540704647","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540704647?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:04","pubTimestamp":1748981069,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025. Stockholders voted to elect Beth Seidenberg, M.D. and Fred E. Cohen, M.D., D. Phil. as Class I directors. Additionally, the appointment of BDO USA, P.C. as the independent registered public accounting firm and independent auditor for the year ending December 31, 2025, was ratified. Both proposals were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL8RxkwJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2539231406","title":"Kyverna Therapeutics Inc. CEO to Present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2539231406","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539231406?lang=en_us&edition=fundamental","pubTime":"2025-05-29 04:02","pubTimestamp":1748462535,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, will be presenting at the Jefferies Global Healthcare Conference in New York, NY. Warner Biddle, the Chief Executive Officer, is scheduled to present on June 4, 2025, at 4:55 p.m. ET. The presentation will be available for live webcast and replay on Kyverna's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL3Pr9S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2538497704","title":"Kyverna Therapeutics’ KYV-101: Promising Developments and First-to-Market Potential in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2538497704","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538497704?lang=en_us&edition=fundamental","pubTime":"2025-05-28 14:35","pubTimestamp":1748414119,"startTime":"0","endTime":"0","summary":"Analyst Thomas Smith from Leerink Partners reiterated a Buy rating on Kyverna Therapeutics, Inc. (KYTX – Research Report) and keeping the price tar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kyverna-therapeutics-kyv-101-promising-developments-and-first-to-market-potential-in-autoimmune-diseases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kyverna-therapeutics-kyv-101-promising-developments-and-first-to-market-potential-in-autoimmune-diseases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2538549936","title":"Kyverna Therapeutics Shares Rise After Upgrade From HC Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2538549936","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538549936?lang=en_us&edition=fundamental","pubTime":"2025-05-28 02:31","pubTimestamp":1748370686,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics  shares were up 16.3% in recent Tuesday trading after HC Wainwright upgraded the stock to buy from neutral and raised its price target to $5 per share from $4.Trading volume was 753,443 shares compared with a daily average of 297,920.Price: 2.64, Change: +0.37, Percent Change: +16.30","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYTX"],"gpt_icon":0},{"id":"2538082468","title":"Kyverna Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2538082468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538082468?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:06","pubTimestamp":1748343960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 27, 2025 07:06 ET (11:06 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2538450663","title":"Kyverna Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2538450663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538450663?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:29","pubTimestamp":1748341779,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nFWN3RZ0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2538508134","title":"Kyverna Therapeutics upgraded to Buy from Neutral at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2538508134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538508134?lang=en_us&edition=fundamental","pubTime":"2025-05-27 18:15","pubTimestamp":1748340930,"startTime":"0","endTime":"0","summary":"H.C. Wainwright upgraded Kyverna Therapeutics (KYTX) to Buy from Neutral with a $5 price target The company is set to produce three sets of data th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0},{"id":"2536068168","title":"Kyverna Therapeutics, Inc. (KYTX) Receives a Hold from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2536068168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536068168?lang=en_us&edition=fundamental","pubTime":"2025-05-19 20:16","pubTimestamp":1747656998,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on Kyverna Therapeutics, Inc. (KYTX – Research Report) today and set a price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kyverna-therapeutics-inc-kytx-receives-a-hold-from-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kyverna-therapeutics-inc-kytx-receives-a-hold-from-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2535080170","title":"Kyverna Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2535080170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535080170?lang=en_us&edition=fundamental","pubTime":"2025-05-14 05:01","pubTimestamp":1747170109,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryKyverna Therapeutics Inc KYTX.OQ reported a quarterly adjusted loss of $1.03 per share for the quarter ended M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL2VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2535087335","title":"Kyverna Therapeutics Provides Business Update And Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535087335","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535087335?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:38","pubTimestamp":1747168690,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Kyverna Therapeutics Inc ::*KYVERNA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS*KYVERNA THERAPEUTICS INC - ANTICIPATES BLA FILING FOR KYV-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nRSDbhb0tr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2535084495","title":"Kyverna Therapeutics Q1 EPS $(1.03) Misses $(0.99) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084495","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084495?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:14","pubTimestamp":1747167267,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(1.03) per share which missed the analyst consensus estimate of $(0.99) by 4.04 percent. This is a 8.04 percent increase over losses of $(1.12) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45390666/kyverna-therapeutics-q1-eps-1-03-misses-0-99-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2535708111","title":"Kyverna Therapeutics Reports Q1 2025 Net Loss of $44.6M, EPS of $1.03 Amid Increased R&D and G&A Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2535708111","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535708111?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:02","pubTimestamp":1747166542,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL1sZ1cc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2535082958","title":"Kyverna Therapeutics Inc: on Track for Topline Data in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535082958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535082958?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:02","pubTimestamp":1747166524,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA97MB4Y:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2535082629","title":"Kyverna Therapeutics Inc - Anticipates Bla Filing for Kyv-101 in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2535082629","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535082629?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:02","pubTimestamp":1747166524,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA97MB4Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2535082625","title":"Kyverna Therapeutics Inc - Reports Cash Runway Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2535082625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535082625?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:02","pubTimestamp":1747166524,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA97MB4Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2534466717","title":"Kyverna Therapeutics Inc  expected to post a loss of $1.11 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534466717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534466717?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:47","pubTimestamp":1746827239,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc  expected to post a loss of $1.11 a share - Earnings Preview Kyverna Therapeutics Inc KYTX.OQ KYTX.O is expected to show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3I9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2527747638","title":"BRIEF-Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527747638","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527747638?lang=en_us&edition=fundamental","pubTime":"2025-04-16 05:57","pubTimestamp":1744754228,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To Time - SEC FilingApril 15  - Kyverna Therapeutics Inc KYTX.O:KYVERNA THERAPEUTICS FILES FOR OFFERING OF UP TO $50 MILLION COMMON STOCK FROM TIME TO TIME - SEC FILINGSource text: [ID:n0000950170-25-054293]Further company coverage: KYTX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT2H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2527420014","title":"Kyverna Therapeutics Files for Offering of up to $50 Mln Common Stock From Time to Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527420014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527420014?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:40","pubTimestamp":1744749639,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT2H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2524531322","title":"Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524531322","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524531322?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:38","pubTimestamp":1743680280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 07:38 ET (11:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0},{"id":"2524423460","title":"Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2524423460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524423460?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:15","pubTimestamp":1743675351,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $4 from $6 and keeps a Neutral rating on the shares following the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-price-target-lowered-to-4-from-6-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"KYTX","fiscalQuarterEnding":"2025/03","expectedEps":-1.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1748404800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2025-06-25","current":-0.948076,"percent":0.828488,"low":-26.836094,"twenty":-8.766622,"median":-2.97247,"eighty":-0.990191,"high":-0.615209,"avg":-5.913816,"sd":7.310849,"marketCap":137868204},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-25","current":-0.948076,"twenty":-8.766622,"median":-2.97247,"eighty":-0.990191,"marketCap":137868204}],"updateTime":1750975214752}}}